New Immunotherapy Fusion Molecule Boosts T-Cells to Fight Tumors
Researchers at the University of Basel have developed a novel immunotherapy. This fusion molecule combines an antibody and interleukin-2, targeting and activating T-cells to fight tumors. The study is published in Science Translational Medicine.
Cancer cells often evade immune detection and disable T-cells using inhibitors. Clara Serger, the lead researcher, combined two strategies to counter this. The fusion molecule blocks these inhibitors and stimulates T-cells, potentially reactivating exhausted defense cells.
The new combo drug aims to make immunotherapy more efficient and gentler. It's currently being tested in a phase 1 clinical trial. Immunotherapies help protect T-cells and mobilize them against cancer. Our immune system naturally recognizes and removes foreign, sick, and mutated cells, including cancer cells.
The University of Basel's new immunotherapy fusion molecule shows promise in targeting and activating T-cells to fight tumors. A phase 1 clinical trial is underway, with results expected to further validate its potential in cancer treatment.
